Osteoarthritis Musculoskeletal Diseases Osteoarthritis (OA)
Conditions
Interventions
Patients are randomised to either 1500 mg of oral glucosamine sulphate or a placebo daily for the duration of two years.
Sponsors
Erasmus Medical Centre (The Netherlands)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients are eligible for participation when they meet one of the American College of Rheumatology (ACR) criteria for osteoarthritis of the hip.
Exclusion criteria
Exclusion criteria: 1. Patients that have already undergone hip replacement surgery 2. Patients on the waiting list for hip replacement surgery 3. Patients that have a Kellgren-Lawrence score of 4 4. Patients with renal or hepatic disease or diabetes mellitus or a disabling co-morbidity
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measures, which are joint space narrowing (JSN), and change in the pain and function score of the Western Ontario McMaster Universities Osteoarthritis index (WOMAC), are determined at baseline and after two years of follow-up during the final assessment. Intermediate measures at three-month intervals throughout the trial are used to study secondary outcome measures. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome measures are changes in WOMAC stiffness score, quality of life, medical consumption, side effects and differences in biomarker CTX-II. | — |
Countries
Netherlands
Outcome results
None listed